TARRYTOWN, N.Y. (AP) — Regeneron Pharmaceuticals Inc. said Tuesday that its German partner Bayer filed for European Union approval of an eye drug the companies are developing.
Bayer AG's Bayer HealthCare unit filed for marketing approval of VEGF Trap-Eye as a treatment for neovascular age-related "wet" macular degeneration, which is the leading cause of blindness in people over the age of 65 in the U.S. The condition causes vision loss as new blood vessels grow beneath the retina and leak blood and fluid, damaging the retina and distorting vision.
Regeneron, which is based in Tarrytown, N.Y., filed for approval in the U.S. in February. Bayer will market the drug outside the U.S. and the companies will share profits. The companies are also studying VEGF Trap-Eye as a treatment for several eye conditions, including "dry" macular degeneration, which is the most common kind of age-related macular degeneration.